Case Reports of Pre-clinical Replication Studies in Metabolism and Diabetes.

Recent articles have highlighted the lack of reproducibility of data from scientific publications. Here we would argue that a better way to describe and also tackle this matter is to use the term "lack of robustness," since it points toward potential solutions. Presenting several case reports, we highlight examples with common underlying issues from Novo Nordisk's experience: animal model variability, reagent quality, and inter-lab variability. We discuss means to prevent these issues and argue for increased collaborative work and transparent manuscript revision procedures. Collectively, we believe these measures will help promote a more rapid and efficient self-corrective process in diabetes drug target research.

[1]  D. Melton,et al.  Resolving Discrepant Findings on ANGPTL8 in β-Cell Proliferation: A Collaborative Approach to Resolving the Betatrophin Controversy , 2016, PloS one.

[2]  C. Begley,et al.  Drug development: Raise standards for preclinical cancer research , 2012, Nature.

[3]  D. Cohen,et al.  Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice. , 1997, The Journal of clinical investigation.

[4]  L. B. Knudsen,et al.  The glucagon-like peptide-1 receptor--or not? , 2013, Endocrinology.

[5]  K. Kaestner,et al.  GABA and Artesunate Do Not Induce Pancreatic α-to-β Cell Transdifferentiation In Vivo. , 2018, Cell metabolism.

[6]  R. Bronson,et al.  Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope , 2011, The Journal of experimental medicine.

[7]  Casper Bo Jensen,et al.  Characterization of the Glucagonlike Peptide-1 Receptor in Male Mouse Brain Using a Novel Antibody and In Situ Hybridization , 2018, Endocrinology.

[8]  B. Hummer,et al.  Pancreatic safety of incretin-based drugs--FDA and EMA assessment. , 2014, The New England journal of medicine.

[9]  A. Ericsson,et al.  Microbiota and reproducibility of rodent models , 2017, Lab Animal.

[10]  O. Madsen,et al.  Long-Term GABA Administration Induces Alpha Cell-Mediated Beta-like Cell Neogenesis , 2017, Cell.

[11]  M. Atkinson,et al.  A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice , 2015, Diabetes.

[12]  M. Lenardo,et al.  Metabolically inactive insulin analogue does not prevent autoimmune diabetes in NOD mice , 2017, Diabetologia.

[13]  A. Talebi,et al.  GABA dramatically improves glucose tolerance in streptozotocin‐induced diabetic rats fed with high‐fat diet , 2018, European journal of pharmacology.

[14]  O. Kuda.  On the Complexity of PAHSA Research. , 2018, Cell metabolism.

[15]  Brian A. Nosek,et al.  Power failure: why small sample size undermines the reliability of neuroscience , 2013, Nature Reviews Neuroscience.

[16]  A. Saghatelian,et al.  Methodological Issues in Studying PAHSA Biology: Masking PAHSA Effects. , 2018, Cell metabolism.

[17]  K. Herold,et al.  Thinking bedside at the bench: the NOD mouse model of T1DM , 2015, Nature Reviews Endocrinology.

[18]  P. Butler,et al.  Glucagon like peptide-1 receptor expression in the human thyroid gland. , 2012, The Journal of clinical endocrinology and metabolism.

[19]  H. Garren,et al.  Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice , 2013, PloS one.

[20]  M. Krashes,et al.  Asprosin is a centrally-acting orexigenic hormone , 2017, Nature Medicine.

[21]  C. Wollheim,et al.  GABA in the Endocrine Pancreas , 2004, The Journal of general physiology.

[22]  S. Helene Richter,et al.  Environmental standardization: cure or cause of poor reproducibility in animal experiments? , 2009, Nature Methods.

[23]  U. Schwahn,et al.  Acute and Repeated Treatment with 5-PAHSA or 9-PAHSA Isomers Does Not Improve Glucose Control in Mice. , 2018, Cell metabolism.

[24]  D. Drucker,et al.  Never Waste a Good Crisis: Confronting Reproducibility in Translational Research. , 2016, Cell metabolism.

[25]  Christoph Bock,et al.  Artemisinins Target GABAA Receptor Signaling and Impair α Cell Identity , 2017, Cell.

[26]  F. Prinz,et al.  Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.

[27]  John P. A. Ioannidis,et al.  A manifesto for reproducible science , 2017, Nature Human Behaviour.

[28]  D. Gary Gilliland,et al.  Drug development and clinical trials—the path to an approved cancer drug , 2012, Nature Reviews Clinical Oncology.

[29]  Sirong He,et al.  Rapamycin/GABA combination treatment ameliorates diabetes in NOD mice. , 2016, Molecular immunology.

[30]  S. Dry,et al.  Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12D Mouse Model , 2012, Diabetes.

[31]  Mark S. Anderson,et al.  The NOD mouse: a model of immune dysregulation. , 2005, Annual review of immunology.

[32]  Yiming Li,et al.  GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes , 2011, Proceedings of the National Academy of Sciences.

[33]  L. Bardram,et al.  GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. , 2014, Endocrinology.

[34]  A. Ponery,et al.  GABA in the endocrine pancreas: cellular localization and function in normal and diabetic rats. , 2002, Tissue & cell.

[35]  C. Donaldson,et al.  Artemether Does Not Turn α Cells into β Cells. , 2018, Cell metabolism.

[36]  H. Garren,et al.  Improved Efficacy of a Tolerizing DNA Vaccine for Reversal of Hyperglycemia through Enhancement of Gene Expression and Localization to Intracellular Sites , 2008, The Journal of Immunology.

[37]  J. Ioannidis.  Why Most Published Research Findings Are False , 2019, CHANCE.

[38]  A. Gore.  Editorial: antibody validation requirements for articles published in endocrinology. , 2013, Endocrinology.

[39]  Christian Skonberg,et al.  Oral insulin (human, murine, or porcine) does not prevent diabetes in the non-obese diabetic mouse. , 2016, Clinical immunology.

[40]  Jonathan C. Cohen,et al.  ANGPTL8/Betatrophin Does Not Control Pancreatic Beta Cell Expansion , 2014, Cell.

[41]  Thiago Lopes-Carvalho,et al.  Tolerogenic insulin peptide therapy precipitates type 1 diabetes , 2017, The Journal of experimental medicine.

[42]  D. Melton,et al.  RETRACTED: Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation , 2013, Cell.

[43]  J. Flier,et al.  Irreproducibility of published bioscience research: Diagnosis, pathogenesis and therapy , 2016, Molecular metabolism.

[44]  M. Baker.  1,500 scientists lift the lid on reproducibility , 2016, Nature.

[45]  J. Ioannidis,et al.  Reproducibility in Science: Improving the Standard for Basic and Preclinical Research , 2015, Circulation research.

[46]  I. Cuthill,et al.  Reporting : The ARRIVE Guidelines for Reporting Animal Research , 2010 .

[47]  D. Drucker.  Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls , 2013, Diabetes.